Tolerability and Efficacy of INSTYLAN in Subjects With Moderate to Severe Hemorrhagic Cystitis

Overview

The purpose of this study is to assess the efficacy and tolerability of INSTYLAN (Sodium Hyaluronate 80mg/50ml) in Patients with early or late symptoms of moderate to severe hemorrhagic cystitis caused by pelvic radiation therapy and/or chemotherapy. The study is conducted in the field of routine clinical practice and will recruit 30 subjects treated with intravesical instillations with INSTYLAN weekly for 6 weeks.

Full Title of Study: “Multicenter Clinical Study of the Efficacy and Tolerability of INSTYLAN (Sodium Hyaluronate 80mg/50ml) in Patients With Early or Late Symptoms of Moderate to Severe Hemorrhagic Cystitis Caused by Pelvic Radiation Therapy and/or Chemotherapy”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 30, 2021

Detailed Description

This is a multicenter single-arm clinical study including male and female subjects with moderate to severe hemorrhagic cystitis caused by pelvic radiation therapy and/or chemotherapy as determined by the physician. A total of 30 subjects are anticipated and will be enrolled in 10 study sites in France. The patients will receive intravesical instillations with INSTYLAN weekly for 6 weeks. The objectives of the study are to assess the efficacy of intravesical instillations of INSTYLAN on the basis of hemorrhagic cystitis symptoms disappearance. The primary endpoint is the evaluation of pain using a verbal rating scale one week and four weeks after treatment versus Baseline.

Interventions

  • Device: INSTYLAN (Sodium Hyaluronate 80mg/50ml)
    • The bladder instillation with INSTYLAN is a treatment involving a sterile solution of Sodium Hyaluronate (80mg/50ml) inserted into the bladder through a catheter and released after a short period of time.

Arms, Groups and Cohorts

  • Experimental: Patients assigned in a single group and treated with 6 instillations of INSTYLAN for 6 weeks
    • Single Group Assignment

Clinical Trial Outcome Measures

Primary Measures

  • Change in the intensity of bladder pain from the beginning of the study (baseline: Week 1) to Week 7
    • Time Frame: Week 7
    • Questionnaire with 5 closed-ended response options: no pain, slight pain, moderate pain, severe pain, very severe pain
  • Change in the intensity of bladder pain from the beginning of the study (baseline: Week 1) to Week 10
    • Time Frame: Week 10
    • Questionnaire with 5 closed-ended response options: no pain, slight pain, moderate pain, severe pain, very severe pain

Secondary Measures

  • Evaluation of hematuria following a rating scale
    • Time Frame: Baseline, week 7 and week 10
    • Verbal rating scale of the colour of the urines: yellow, pink or red-brownish
  • Evaluation of number of micturitions / 24 hours
    • Time Frame: Baseline, week 7 and week 10
    • Voiding diary sheet for each 24-hour period
  • Evaluation of urgency of micturitions following a rating scale
    • Time Frame: Baseline, week 7 and week 10
    • Verbal rating scale (slight, moderate, important)

Participating in This Clinical Trial

Inclusion Criteria

  • Males and females, at least 18 years, – Patients who provided signed written informed consent, which includes compliance with requirements listed in the consent form, – Patients with diagnosis of Hemorrhagic Cystitis, – Patients with diagnosis of bladder pain (pressure or pelvic discomfort) with at least one other urinary symptom (need to urinate right away (urgency), often (frequency), or both). Exclusion Criteria:

  • Patients with Post-void residual (PVR) urine volume > 200ml, – Patients presently treated with intravesical treatment (replenishment therapy with glycosaminoglycans), – Patients receiving HyperBaric Oxygen Therapy (HBOT), – Patients with neurogenic bladder, – Patients treated with neuromodulation techniques within the last six months, – Patients undergoing or scheduled for radiation therapy, brachytherapy, chemotherapy or treatment with BCG or with Mitomycin-C, – Patients suffering from lower urinary infections (UTIs), – Patients with unstable cardiovascular disease, – Patients with any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • LIDDE Therapeutics
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Marc FOURMARIER, MD, Principal Investigator, Aix en Provence Hospital Center (Aix en Provence)
  • Overall Contact(s)
    • François SCHUTZE, PhD, +33 (0)6 83 54 01 42, fr.schutze@liddetherapeutics.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.